Anti-tumor agents 255: Novel glycyrrhetinic acid-dehydrozingerone conjugates as cytotoxic agents

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 18, 2007, Pages 6193-6199

  Tatsuzaki, Jin ^a   Taniguchi, Masahiko ^a   Bastow, Kenneth F ^a   Nakagawa Goto, Kyoko ^a   Morris Natschke, Susan L ^a   Itokawa, Hideji ^a   Baba, Kimiye ^b   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Conjugation; Cytotoxicity; Dehydrozingerone; Glycyrrhetinic acid

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DEHYDROZINGERONE; GLYCYRRHETINIC ACID; GLYCYRRHETINIC ACID DERIVATIVE; OLEANOLIC ACID DERIVATIVE; TRITERPENOID; URSOLIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN KB; CULTURE MEDIUM; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; ESTERIFICATION; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; CYTOTOXINS; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCYRRHETINIC ACID; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; STYRENES; TUMOR CELLS, CULTURED;

EID: 34447629229     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.06.027     Document Type: Article

References (20)

1. Finney R.S., and Tarnoky A.L. J. Pharm. Pharmacol. 12 (1960) 49
2. Pompei R., Flore O., Marccialis M.A., Pani A., and Loddo B. Nature 281 (1979) 689
3. Tanaka S., Uno C., Akimoto M., Tabata M., Honda C., and Kamisako W. Planta Med. 57 (1991) 527
4. Ichikawa Y., Mizoguchi Y., Kioka K., Kobayashi K., Tomekawa K., Morosawa S., and Yamamoto S. Arerugi 38 (1989) 365
5. Okamoto H., Yoshida D., and Mizusaki S. Cancer Lett. 19 (1983) 47
6. Liu J. J. Ethnopharm. 49 (1995) 57
7. Liu J. J. Ethnopharm. 100 (2005) 92 and references therein
8. Motohashi N., Yamagami C., Tokuda H., Konoshima T., Okuda Y., Okuda M., Mukainaka T., Nishino H., and Saito Y. Cancer Lett. 134 (1998) 37
9. Choi S.K. Synthetic Multivalent Molecules (2004), Wiley-Interscience, New York
10. Bastow K.F., Wang H.K., Cheng Y.C., and Lee K.H. Bioorg. Med. Chem. 5 (1997) 1481
11. Chang J.Y., Guo X., Chen H.X., Jiang Z., Fu Q., Wang H.K., Bastow K.F., Zhu X.K., Guan J., Lee K.H., and Cheng T.C. Biochem. Pharm. 59 (2000) 497
12. Shi Q., Wang H.K., Bastow K.F., Tachibana Y., Chen K., Lee F.Y., and Lee K.H. Bioorg. Med. Chem. 9 (2001) 2999
13. Ohtsu H., Nakanishi Y., Bastow K.F., Lee F.Y., and Lee K.H. Bioorg. Med. Chem. 11 (2003) 1851
14. Nakagawa-Goto K., Nakamura S., Bastow K.F., Nyarko A., Peng C.Y., Lee Y.F., Lee F.C., and Lee K.H. Bioorg. Med. Chem Lett. 17 (2007) 2894-2898
15. Nakagawa-Goto, K.; Yamada, K.; Nakamura, S.; Chen, T. H.; Bastow, K. F.; Wang, S. C.; Hung, M. C.; Lee, F. Y.; Lee, F. C.; Lee, K. H. Bioorg. Med. Chem. Lett., in press.
16. 50 value, the drug concentration that reduced the absorbance by 50%, was interpolated from dose-response data. Each test was performed in duplicate, and absorbance readings varied no more than 5% between replicates.
17. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simo R.M., Tosini S., Skehan P., Scudiero P.A., Monks A., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1113
18. Ferguson P.J., Fisher M.H., Stephenson J., Li D.H., Zhou B.S., and Cheng Y.C. Cancer Res. 48 (1988) 5956
19. Beidler D.R., Chang J.Y., Zhou B.S., and Cheng Y.C. Cancer Res. 56 (1996) 345
20. Elias G., and Rao M.N.A. Eur. J. Med. Chem. 23 (1988) 379